Feb 2019 - Salipro Biotech signs multi-target agreement with an additional global pharma company. Salipro Biotech will apply its expertise and its unique membrane protein technology to advance programs on challenging targets selected by the pharmaceutical partner.
July 2018 - New Publication: Salipro approach enabled scientists at UCSF and UT-Southwestern to resolve the 180 kDa mitochondrial calcium uniporter to 3.8 Å resolution. "Saposin yielded a marked improvement in the structure". Link: www.nature.com/articles/s41586-018-0333-6
Feb 2018 - Out now: Salipro® goes Biacore™ systems - See the results of our collaboration with GE Healthcare on antibody binding to membrane proteins, detergent-free, in our Application Note: http://www.salipro.com/application_note.html
Nov 2017 -Salipro® goes Biacore™ systems: Find out more about our collaboration with GE Healthcare at the PEGS 2017 meeting in Lisbon. We will present kinetic profiles of antibody binding to membrane proteins, detergent-free.
Oct 2017 - Salipro® for functional studies of a GPCR with NMR. Half-life of GPCR in Salipro® extended from 1.5 to 30 days. Check out the latest paper on our technology by Nietlispach et al: http://pubs.acs.org/doi/10.1021/jacs.7b06730
Oct 2017 - Salipro Biotech is presenting at the Genesis Drug Discovery meeting in Frankfurt (11.-12.10.2017)
Sept 2017 - Meet Salipro Biotech at the Nordic Life Science Days 2017 in Malmö (12.-14.09.2017)
Jan 2017 - We're growing and moving to new premises in central Stockholm. With more lab space and offices, we're located at the Greenhouse Labs at the Royal Institute of Technology in Stockholm. Location
Sept 2016: Prof Poul Nissen joins the advisory board.
Aug 2016: Salipro Biotech AB successfully completes a first feasibility study with AstraZeneca. Stefan Geschwindner, Principal Scientist, AstraZeneca R&D Gothenburg: “We have been impressed by the fact that Salipro Biotech is able to work both with detergent-solubilised material as well as with crude cell-membranes and furthermore demonstrated good feasibility to generate non-aggregated membrane proteins in a detergent-free form. This forms an excellent basis for the next steps that will include both structural and biophysical work.”
Aug 2016: Håkan Garpenstrand joins the advisory board for business development and corporate strategy.
May 2016: Salipro Biotech AB enters into study agreement with AstraZeneca.